网址：www.grandwaylaw.com 上海市黄浦区中山东二路 600 号 BFC 外滩金融中心 S2 栋 23 层 23/F S2 Building, The Bund Finance Center, No. 600, Zhongshan No. 2, Road(E), Huangpu District, Shanghai, 200010, China 电话：021-23122000 传真：021-23122100 邮编：200010 北京 上海 深圳 成都 西安 杭州 香港 北京国枫（上海）律师事务所 关于睿智医药科技股份有限公司 2024 年第一次临时股东大会的 法律意见书 国枫律股字[2024]B0001 号 致：睿智医药科技股份有限公司（贵公司） 北京国枫（上海）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2024 年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司股东大会规则》（以下简称《股东大会规则》）、《律师事务所从事证券法 律业务管理办法》《律师事务所证券法律业务执业规则（试行）》等相 ...

睿智医药科技股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决提案的情形。 证券代码：300149 证券简称：睿智医药 公告编号：2024-02 出席现场会议的股东及股东代表 4 人，所持有表决权的股份 520,600 股，占公司 总股本的 0.1042%；参加网络投票的股东 12 人，所持有表决权的股份 103,326,615 股， 占公司总股本的 20.6745％。 2、本次股东大会无变更提案的情况。 一、会议召开和出席情况 1、召开方式：本次会议采取现场投票与网络投票相结合的方式。 2、现场会议地点：上海市浦东新区张江高科技园区金科路 2829 号金科中心 A 栋 上海睿智化学研究有限公司 3、现场会议召开时间：2024 年 1 月 10 日下午 14:30 4、网络投票时间：2024 年 1 月 10 日。其中，通过深圳证券交易系统进行网络投 票的具体时间为 2024 年 1 月 10 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通 ...

证券代码：300149 证券简称：睿智医药 公告编号：2024-04 睿智医药科技股份有限公司 关于选举董事长、聘任首席执行官（CEO）暨调整 董事会专门委员会成员的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、选举董事长的情况 四、独立意见 公司独立董事对公司第五届董事会第三十七次会议相关事项进行了认真审 议并发表了如下独立意见： 经认真审阅，我们认为：WOO SWEE LIAN 先生具备履行职责的任职条件 及工作经验，符合《公司法》及其他法律法规关于担任公司高级管理人员的相关 规定。因此，我们一致同意公司聘任 WOO SWEE LIAN 先生担任公司首席执行 官（CEO）。 睿智医药科技股份有限公司（以下简称"公司"）于 2024 年 1 月 10 日召开 第五届董事会第三十七次会议，会议审议通过了《关于选举第五届董事会董事长 的议案》，全体董事一致同意选举 WOO SWEE LIAN 先生（简历详见附件）为 公司第五届董事会董事长，任期自本次董事会审议通过之日起至第五届董事会届 满之日止。 根据《公司章程》等法律法规的相关规定，董事长为公司的法定代 ...

证券代码：300149 证券简称：睿智医药 公告编号：2024-03 睿智医药科技股份有限公司 三、审议通过了《关于调整董事会专门委员会成员的议案》 根据公司实际情况，董事会同意对战略委员会、薪酬与考核委员会成员进行 调整，审计委员会成员不变。由 WOO SWEE LIAN 先生担任公司董事会战略委 员会主任委员、薪酬与考核委员会委员，WOO SWEE LIAN 先生董事会专门委 员会的任期自本次董事会审议通过之日起至第五届董事会届满之日止 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第五届董事会第三十七次会 议于 2024 年 1 月 10 日当日以现场结合通讯方式召开。因拟审议事项紧急，经与 会董事同意，豁免本次董事会通知时限。会议应到董事 7 人，实到 7 人，本次会 议由公司代理董事长樊世新先生主持，并就紧急通知的原因在本次会议上作出了 说明。公司监事、高级管理人员列席了会议。本次会议召集与召开符合有关法律、 行政法规、部门规章和《公司章程》的有关规定。与会董事经认真审议，形成决 议如下： 一、审议通过了《关于 ...

证券代码：300149 证券简称：睿智医药 公告编号：2024-01 《上市公司信息披露管理办法》第三条第一款、《企业会计准则第 8 号——资产 减值》第五条等相关规定。 整改措施：公司子公司凯惠药业动物房于 2020 年拆除，在当年年末未及时进 行资产报废处理，而是于 2021 年完成工程验收后才进行了资产报废处理。该事项 涉及金额 381.17 万元，金额占 2020 年末公司资产总额 0.09%；该事项同时影响 固定资产和商誉两个科目，且方向相反，两相抵消后对公司 2020 年度的财务状 况、经营成果和现金流量等财务指标未造成重大影响。 针对上述问题，公司组织相关人员认真学习《企业会计准则》及《企业内部 关于对广东证监局警示函整改报告的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于 2023 年 12 月 22 日收到 中国证券监督管理委员会广东监管局下发的《关于对睿智医药科技股份有限公司、 采取出具警示函措施的决定》（【2023】15 号）（以下简称"《警示函》"）， 要求公司就《警示函》中提出的问题进行 ...

Financial Performance - The company's total revenue for 2020 was approximately CNY 1.48 billion, representing an increase of 11.58% compared to CNY 1.33 billion in 2019[17]. - The net profit attributable to shareholders for 2020 was CNY 154.55 million, up 11.25% from CNY 138.92 million in 2019[17]. - The diluted earnings per share for 2020 was CNY 0.31, reflecting a 10.71% increase from CNY 0.28 in 2019[17]. - The company reported a significant increase in operating cash flow, with a net cash flow from operating activities of CNY 343.16 million, up 59.56% from CNY 215.07 million in 2019[17]. - As of the end of 2020, the total assets of the company reached CNY 4.12 billion, a 9.39% increase from CNY 3.77 billion at the end of 2019[17]. - The company achieved a total revenue of 1,481.59 million CNY in 2020, representing a year-on-year growth of 11.58%[60]. - The net profit attributable to shareholders was 154.55 million CNY, an increase of 11.25% compared to the previous year[60]. - The pharmaceutical R&D and production service segment generated revenue of 1,213.50 million CNY, up 10.52% year-on-year, with a significant growth of 15.96% in the last three quarters[62]. - The microbiome nutrition and medical segment reported revenue of 279.94 million CNY, reflecting a growth of 20.47%, with international business revenue increasing by 65.61%[60]. - The company reported a total revenue of 3,005 million RMB for the year 2020, representing a growth of 11.17% compared to the previous year[170]. Dividend Distribution - The company plans to distribute a cash dividend of 0.2 yuan per 10 shares to all shareholders, based on a total of 499,776,892 shares[5]. - The company plans to distribute a cash dividend of 0.7 yuan per share (including tax), totaling 34,984,382.44 yuan for the year 2020[142]. - The cash dividend for 2020 represents 22.64% of the net profit attributable to ordinary shareholders, which is 154,550,403.78 yuan[144]. - In 2019, the company did not distribute any cash dividends, while in 2018, it distributed 34,984,382.44 yuan, accounting for 21.72% of the net profit[144]. - The total number of shares for the dividend distribution is based on 499,776,892 shares as of December 31, 2020[142]. - The company has a history of consistent cash dividend payments over the past three years, with a notable increase in 2020 compared to 2019[144]. Risk Management - The company faces risks including a decline in service demand, loss of core technology and management personnel, and fluctuations in raw material prices[5]. - The company has a detailed section on risks and countermeasures in its report, highlighting potential operational risks[5]. - The company acknowledges the risk of new technology development failures, which could negatively affect its business and financial outlook if it fails to innovate effectively[124]. - Regulatory compliance is critical, as failure to meet standards could lead to penalties and loss of project qualifications, impacting the company's reputation and financial performance[126]. - The company is exposed to raw material price fluctuations, particularly for sucrose and lactose, which could affect production costs and profit margins if not managed properly[126]. - The company faces foreign exchange risks primarily related to USD and EUR, with most service costs denominated in RMB, potentially impacting profit margins if RMB appreciates against USD[130]. - The company is subject to various legal regulations for drug development and production, and failure to obtain necessary approvals could lead to significant adverse impacts on business and financial performance[131]. Governance and Compliance - The company has a comprehensive governance structure, with all board members present for the report's approval[5]. - The report includes a commitment to ensuring the accuracy and completeness of financial reports by the management team[4]. - The company has established measures to ensure the independence of its assets, personnel, and financial operations[146]. - The company emphasizes compliance with legal and regulatory requirements in its related party transactions and financial disclosures[146]. - The controlling shareholder committed to avoiding any business competition with Quantum High-Tech and its subsidiaries for 60 months post-transaction[148]. - The company has committed to respecting the actual control of the listed company by its existing controllers for a period of 60 months post-transaction[151]. Market Expansion and Development - The company is actively developing personalized micro-ecological health management plans based on gut microbiome analysis[37]. - The company has established a leading market share in the domestic prebiotic ingredient market with its QHT® brand[37]. - The company plans to enhance its operational system to better align with the domestic pharmaceutical market[116]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[149]. - A strategic acquisition of a smaller biotech firm was completed, which is anticipated to enhance the company's R&D capabilities and add 200 million RMB in annual revenue[150]. Research and Development - The company has advanced its biological drug research service, pushing over 100 therapeutic antibodies into various research stages[33]. - The company has developed multiple core technologies in the prebiotic sector, establishing a patent system centered on immobilized enzyme production of prebiotics[43]. - The company is focused on continuous innovation in its technology platforms, including the development of DNA-encoded compound libraries and PROTAC technology platforms, to enhance its drug development solutions[122]. - The company has established a project management department to enhance communication with clients during drug development, ensuring quality and efficiency in project delivery[190]. - The company achieved AAALAC certification for its animal welfare practices, demonstrating adherence to international standards in animal management and use[192]. Social Responsibility and Environmental Compliance - The company actively participated in social responsibility initiatives, donating over CNY 1 million in probiotics to support COVID-19 relief efforts[193]. - The company maintains compliance with environmental regulations through regular monitoring and third-party assessments[197]. - The hazardous waste generated by Shanghai Ruizhi includes medical waste and other types, with all hazardous waste disposed of through qualified disposal companies in 2020[196]. - The company conducts annual soil and groundwater testing through a third-party company with CMA qualifications, and all monitored factors are within the limits[197]. Investment and Financial Strategy - The company has invested a total of 10,989,778.31 USD in the ShangPharma Capital LP fund as of December 31, 2020[174]. - The company has a 30% stake in the ShangPharma Capital LP fund, which has a total scale of 100 million USD[174]. - The company reported a net profit of 837.55 million USD from its investments in the biopharmaceutical funds[173]. - The company is focused on maintaining a balance between rental income and operational costs associated with leased properties[180].

Financial Performance - The company reported a significant loss primarily due to a large goodwill impairment and an increase in period expenses[4]. - The company's revenue for 2021 was CNY 1,690,677,943.33, representing a 14.11% increase compared to CNY 1,481,591,872.64 in 2020[22]. - The net profit attributable to shareholders for 2021 was a loss of CNY 402,245,074.78, a decrease of 360.27% from a profit of CNY 154,550,403.78 in 2020[22]. - The net cash flow from operating activities for 2021 was CNY 378,219,891.25, which is a 10.22% increase from CNY 343,160,357.56 in 2020[22]. - The total assets at the end of 2021 were CNY 4,217,591,526.68, a 2.33% increase from CNY 4,121,581,017.24 at the end of 2020[22]. - The net assets attributable to shareholders decreased by 19.09% to CNY 1,964,444,590.44 at the end of 2021 from CNY 2,427,903,737.42 at the end of 2020[22]. - The basic earnings per share for 2021 was -CNY 0.81, compared to CNY 0.31 in 2020, reflecting a decline of 361.29%[22]. - The company reported a net loss attributable to shareholders of -40,224.51 million CNY, with a significant goodwill impairment of 36,760 million CNY impacting profitability[45]. Business Strategy and Focus - The company plans to focus on its core business to enhance its industry position, competitive capabilities, and sustainable development[4]. - The company plans to divest its prebiotic business to focus on CRO/CDMO services, with the sale of Quantum Gaoke (Guangdong) Bio Co., Ltd. approved by shareholders[35]. - The company aims to enhance its integrated pharmaceutical R&D service capabilities to foster long-term strategic partnerships with clients[67]. - The company is focusing on expanding its market presence and enhancing its product offerings, as indicated by the strategic appointments in its leadership team[145]. - The company is actively pursuing opportunities for mergers and acquisitions to bolster its market position and expand its product portfolio[147]. Risks and Challenges - The company faces various risks, including a decline in service demand, loss of core technology and management personnel, and risks related to new technology development failures[5]. - The audit report from Ernst & Young Huaming indicates a going concern uncertainty, highlighting the need for careful investor consideration[4]. - The company acknowledges the risk of goodwill impairment from its acquisition of Shanghai Ruizhi, emphasizing the need for effective resource integration to mitigate this risk[117]. - The company faces risks related to declining demand for pharmaceutical R&D services, which could significantly impact its business if industry growth slows[112]. - Natural disasters and public health emergencies, such as COVID-19, pose risks to the company's operations, particularly in facilities located in China, the US, and Denmark[123]. Governance and Management - The company has a clear governance structure that aligns with regulatory standards, with no significant discrepancies noted[137]. - The company has appointed a dedicated board secretary to manage investor relations and ensure effective communication with shareholders[135]. - The company has established a performance evaluation and incentive mechanism to link executive compensation with company performance, enhancing operational efficiency and management standards[134]. - The company reported a significant leadership change with the election of Zeng Xianwei as Chairman on November 18, 2021, and the appointment of Hua Fengmao as CEO on July 8, 2021[143]. - The company has undergone significant restructuring in its management team, which may lead to new strategic initiatives and operational efficiencies[148]. Research and Development - The company has developed a database of 8 million small molecules for virtual screening, enhancing its drug design capabilities[39]. - The company has established a comprehensive end-to-end service capability for biopharmaceuticals, covering early discovery to large-scale production[60]. - The company has established several research platforms, including an antibody-drug conjugate (ADC) R&D service platform and a large-scale recombinant monoclonal antibody R&D platform[193][196]. - The company is committed to enhancing its research and development capabilities, as evidenced by the appointment of experienced professionals in key positions[147]. Environmental Management - The company emphasizes environmental management, adhering to the Environmental Protection Law of the People's Republic of China, and aims to maximize resource efficiency while minimizing environmental impact[200]. - The company has established hazardous waste storage facilities with protective measures for the collection of hazardous waste generated[186]. - The company has implemented an environmental monitoring scheme, including annual monitoring of waste gas and quarterly monitoring of wastewater and noise, with third-party verification conducted[198]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[200]. Shareholder Relations and Dividends - No cash dividends, stock bonuses, or capital increases from reserves will be distributed to shareholders[6]. - The company reported a total cash dividend amount of ¥20,443,281.30 through share repurchase, with no cash dividends or stock bonuses distributed to shareholders for the fiscal year 2021[173]. - The company incurred losses in 2021 and decided not to distribute profits to ensure sufficient funding for long-term development[174]. - The company has a clear cash dividend policy that aligns with its articles of association and shareholder resolutions[172].

证券代码：300149 证券简称：睿智医药 公告编号：2023-64 睿智医药科技股份有限公司 关于持股 5%以上股东及其一致行动人减持股份计划的预披露公告 持股5%以上股东上海睿昀企业管理中心（有限合伙）及其一致行动人上海睿 钊企业管理中心（有限合伙）保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于近日收到公司持股 5%以 上股东上海睿昀企业管理中心（有限合伙）（以下简称"睿昀投资"）及其一致 行动人上海睿钊企业管理中心（有限合伙）（以下简称"睿钊投资"）出具的《关 于股份减持计划告知函》，睿昀投资和睿钊投资计划在本公告披露之日起十五个 交易日后的 3 个月内以集中竞价交易方式减持公司股份数量合计不超过 4,990,000 股，即不超过公司总股本的 1%。现将相关情况公告如下： 一、拟减持股东的基本情况 1、股东名称：上海睿昀企业管理中心（有限合伙）、上海睿钊企业管理中心 （有限合伙） | 序号 | 股东名称 | 持股数量（股） ...

证券代码：300149 证券简称：睿智医药 公告编号：2023-63 睿智医药科技股份有限公司 关于 2024 年第一次临时股东大会增加临时提案 暨股东大会补充通知的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第五届董事会第三十五次会 议决定于 2024 年 1 月 10 日以现场表决与网络投票相结合的方式召开公司 2024 年第一次临时股东大会，具体内容详见 2023 年 12 月 26 日在中国证监会指定创 业板信息披露网站发布的《关于召开 2024 年第一次临时股东大会的通知》。 2023 年 12 月 29 日，公司董事会接到股东 MEGA STAR CENTRE LIMITED 提交的《关于提请增加股东大会临时提案的函》，其从提高公司决策效率的角度 考虑，提请公司董事会将《关于补选非独立董事的议案》作为临时提案提交公司 2024 年第一次临时股东大会审议，提议本公司 2024 年第一次临时股东大会所审 议的第一项议案"关于补选非独立董事的议案"增加一名候选人俞熔先生。该议 案已经公司于 2023 年 1 ...

证券代码：300149 证券简称：睿智医药 公告编号：2023-61 睿智医药科技股份有限公司 第五届董事会第三十六次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）第五届董事会第三十六次会 议于 2023 年 12 月 29 日以电话、电子邮件方式送达，并于当日以通讯方式召开。 因拟审议事项紧急，经与会董事同意，豁免本次董事会通知时限。会议应到董事 5 人，实到 5 人，本次会议由公司代理董事长樊世新先生主持，并就紧急通知的 原因在本次会议上作出了说明。公司监事、高级管理人员列席了会议。本次会议 召集与召开符合有关法律、行政法规、部门规章和《公司章程》的有关规定。与 会董事经认真审议，形成决议如下： 董事会 2023 年 12 月 29 日 附件： 简历 一、审议通过了《关于补选非独立董事的议案》 根据《中华人民共和国公司法》《上市公司自律监管指引第 2 号——创业板 上市公司规范运作》《公司章程》等有关规定，经公司股东 MEGA STAR CENTRE LIMITED 提名，拟提名俞熔先生（简历详见附件） ...